Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01613040 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 169
- Enrollment target
NCT01613040: Completed Phase 1 study, sponsored by Hoffmann-La Roche.
NCT01613040 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 169 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (182% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01613040, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 169 participants
- Enrollment target
Study Summary
This multiple-center, multiple-dose, randomized, double-blind, double-dummy, placebo-controlled, positive-controlled, parallel group study will investigate the effect of RO4917838 on the QTc interval in healthy volunteers. Healthy volunteers will be randomized to one of 4 treatment arms; Arm A: low dose of RO4917838, Arm B: high dose of RO4917838, Arm C: placebo to RO4917838 and moxifloxacin on Day 1, Arm D: placebo to RO4917838 and moxifloxacin on Day 11. The anticipated time on study treatment is 11 days.
Interventions
- DRUG Moxifloxacin
- DRUG RO4917838
- DRUG RO4917838 placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
What the finished NCT01613040 record still lists
NCT01613040 is an interventional study that assigns participants to a tested intervention. The registered 169 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (182% higher).
The record links to 0 conditions, and to 3 interventions - of which Moxifloxacin is the first listed.
NCT01613040 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01613040 about?
NCT01613040 is a clinical study titled "A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers". This multiple-center, multiple-dose, randomized, double-blind, double-dummy, placebo-controlled, positive-controlled, parallel group study will investigate the effect of RO4917838 on the QTc interval in healthy volunteers. Healthy volunteers will be randomized to one of 4 treatment arms; Arm A: low ...
What is the current status of trial NCT01613040?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 169 participants. The study started on 2009-01. Estimated completion is 2009-07.
What interventions are being tested in trial NCT01613040?
The interventions under investigation include: Moxifloxacin (DRUG), RO4917838 (DRUG), RO4917838 placebo (DRUG).
Who is sponsoring clinical trial NCT01613040?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01613040's enrollment target sits among peer trials
169 326th of 2000 higher than 1,675 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06191484 · 169 participants · NA
Risk and Resilience to Suicide Following Late-Life Spousal Bereavement
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia